DNA methylation has been linked to high-risk clinical features in JMML, such as older age, high white blood cell count, low platelet count, and mutations in PTPN11 and RAS-related genes, along with abnormal karyotypes, all correlating with poorer outcomes (20, 26–28). Here, PTPN11 is linked to juvenile myelomonocytic leukemia.